Progress and strategies for patients with relapsed and refractory acute myeloid leukemia

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: The treatment of patients with refractory or relapsed acute myeloid leukemia remains challenging. Management of these patients must take into account patient and leukemia-related factors in order to organize a comprehensive approach to treatment. Many new therapies are under study. RECENT FINDINGS: New molecular markers that represent mutations or gene overexpression have been identified including FMS-like tyrosine kinase-3 and nucleophosmin, which will enhance our ability to more accurately prognosticate for patients with acute myeloid leukemia. Monoclonal antibodies and peptide vaccination with leukemia-associated antigens bring the hope of increasing the remission and cure rates for patients with acute myeloid leukemia. The use of reduced-intensity conditioning blood or marrow transplantation is finding a broader role in the treatment of acute myeloid leukemia. SUMMARY: Patients with relapsed or refractory acute myeloid leukemia should be entered on clinical trials whenever feasible given the lack of consensus on the most effective treatment in this setting. Blood and marrow transplantation remains the only known curative therapy for these patients and the use of reduced-intensity conditioning blood or marrow transplantation offers the option of this approach to older and more infirm patients. Greater understanding of the biology of acute myeloid leukemia will provide new molecular targets of use in diagnosis, monitoring, and for the development of new, targeted therapies.

Original languageEnglish (US)
Pages (from-to)130-137
Number of pages8
JournalCurrent Opinion in Hematology
Volume14
Issue number2
DOIs
StatePublished - Mar 2007

Fingerprint

Acute Myeloid Leukemia
Transplantation
Bone Marrow
Therapeutics
Leukemia
Protein-Tyrosine Kinases
Vaccination
Monoclonal Antibodies
Clinical Trials
Antigens
Peptides
Mutation
Genes

Keywords

  • Blood or marrow transplantation
  • Gene expression profiles
  • Immunotherapy
  • Molecular targets
  • Reduced intensity conditioning

ASJC Scopus subject areas

  • Hematology

Cite this

Progress and strategies for patients with relapsed and refractory acute myeloid leukemia. / Litzow, Mark R.

In: Current Opinion in Hematology, Vol. 14, No. 2, 03.2007, p. 130-137.

Research output: Contribution to journalReview article

@article{7c49cb41a52848749bf5cab9f5f06615,
title = "Progress and strategies for patients with relapsed and refractory acute myeloid leukemia",
abstract = "PURPOSE OF REVIEW: The treatment of patients with refractory or relapsed acute myeloid leukemia remains challenging. Management of these patients must take into account patient and leukemia-related factors in order to organize a comprehensive approach to treatment. Many new therapies are under study. RECENT FINDINGS: New molecular markers that represent mutations or gene overexpression have been identified including FMS-like tyrosine kinase-3 and nucleophosmin, which will enhance our ability to more accurately prognosticate for patients with acute myeloid leukemia. Monoclonal antibodies and peptide vaccination with leukemia-associated antigens bring the hope of increasing the remission and cure rates for patients with acute myeloid leukemia. The use of reduced-intensity conditioning blood or marrow transplantation is finding a broader role in the treatment of acute myeloid leukemia. SUMMARY: Patients with relapsed or refractory acute myeloid leukemia should be entered on clinical trials whenever feasible given the lack of consensus on the most effective treatment in this setting. Blood and marrow transplantation remains the only known curative therapy for these patients and the use of reduced-intensity conditioning blood or marrow transplantation offers the option of this approach to older and more infirm patients. Greater understanding of the biology of acute myeloid leukemia will provide new molecular targets of use in diagnosis, monitoring, and for the development of new, targeted therapies.",
keywords = "Blood or marrow transplantation, Gene expression profiles, Immunotherapy, Molecular targets, Reduced intensity conditioning",
author = "Litzow, {Mark R}",
year = "2007",
month = "3",
doi = "10.1097/MOH.0b013e32801684ef",
language = "English (US)",
volume = "14",
pages = "130--137",
journal = "Current Opinion in Hematology",
issn = "1065-6251",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Progress and strategies for patients with relapsed and refractory acute myeloid leukemia

AU - Litzow, Mark R

PY - 2007/3

Y1 - 2007/3

N2 - PURPOSE OF REVIEW: The treatment of patients with refractory or relapsed acute myeloid leukemia remains challenging. Management of these patients must take into account patient and leukemia-related factors in order to organize a comprehensive approach to treatment. Many new therapies are under study. RECENT FINDINGS: New molecular markers that represent mutations or gene overexpression have been identified including FMS-like tyrosine kinase-3 and nucleophosmin, which will enhance our ability to more accurately prognosticate for patients with acute myeloid leukemia. Monoclonal antibodies and peptide vaccination with leukemia-associated antigens bring the hope of increasing the remission and cure rates for patients with acute myeloid leukemia. The use of reduced-intensity conditioning blood or marrow transplantation is finding a broader role in the treatment of acute myeloid leukemia. SUMMARY: Patients with relapsed or refractory acute myeloid leukemia should be entered on clinical trials whenever feasible given the lack of consensus on the most effective treatment in this setting. Blood and marrow transplantation remains the only known curative therapy for these patients and the use of reduced-intensity conditioning blood or marrow transplantation offers the option of this approach to older and more infirm patients. Greater understanding of the biology of acute myeloid leukemia will provide new molecular targets of use in diagnosis, monitoring, and for the development of new, targeted therapies.

AB - PURPOSE OF REVIEW: The treatment of patients with refractory or relapsed acute myeloid leukemia remains challenging. Management of these patients must take into account patient and leukemia-related factors in order to organize a comprehensive approach to treatment. Many new therapies are under study. RECENT FINDINGS: New molecular markers that represent mutations or gene overexpression have been identified including FMS-like tyrosine kinase-3 and nucleophosmin, which will enhance our ability to more accurately prognosticate for patients with acute myeloid leukemia. Monoclonal antibodies and peptide vaccination with leukemia-associated antigens bring the hope of increasing the remission and cure rates for patients with acute myeloid leukemia. The use of reduced-intensity conditioning blood or marrow transplantation is finding a broader role in the treatment of acute myeloid leukemia. SUMMARY: Patients with relapsed or refractory acute myeloid leukemia should be entered on clinical trials whenever feasible given the lack of consensus on the most effective treatment in this setting. Blood and marrow transplantation remains the only known curative therapy for these patients and the use of reduced-intensity conditioning blood or marrow transplantation offers the option of this approach to older and more infirm patients. Greater understanding of the biology of acute myeloid leukemia will provide new molecular targets of use in diagnosis, monitoring, and for the development of new, targeted therapies.

KW - Blood or marrow transplantation

KW - Gene expression profiles

KW - Immunotherapy

KW - Molecular targets

KW - Reduced intensity conditioning

UR - http://www.scopus.com/inward/record.url?scp=33846594363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846594363&partnerID=8YFLogxK

U2 - 10.1097/MOH.0b013e32801684ef

DO - 10.1097/MOH.0b013e32801684ef

M3 - Review article

VL - 14

SP - 130

EP - 137

JO - Current Opinion in Hematology

JF - Current Opinion in Hematology

SN - 1065-6251

IS - 2

ER -